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Abstract
Background: Autosomal dominant inheritance of germline mutations in the bone morphogenetic protein
receptor type 2 (BMPR2) gene are a major risk factor for pulmonary arterial hypertension (PAH). While
previous studies demonstrated a difference in severity between BMPR2 mutation carriers and noncarriers,
it is likely disease severity is not equal among BMPR2 mutations. We hypothesized that patients with
missense BMPR2 mutations have more severe disease than those with truncating mutations.
Methods: Testing for BMPR2 mutations was performed in 169 patients with PAH (125 with a family
history of PAH and 44 with sporadic disease). Of the 106 patients with a detectable BMPR2 mutation,
lymphocytes were available in 96 to functionally assess the nonsense-mediated decay pathway of RNA
surveillance. Phenotypic characteristics were compared between BMPR2  mutation carriers and
noncarriers, as well as between those carriers with a missense versus truncating mutation.
Results: While there was a statistically significant difference in age at diagnosis between carriers and
noncarriers, subgroup analysis revealed this to be the case only for females. Among carriers, there was no
difference in age at diagnosis, death, or survival according to exonic location of the BMPR2 mutation.
However, patients with missense mutations had statistically significant younger ages at diagnosis and death,
as well as shorter survival from diagnosis to death or lung transplantation than those with truncating
mutations. Consistent with this data, the majority of missense mutations were penetrant prior to age 36
years, while the majority of truncating mutations were penetrant after age 36 years.
Conclusion: In this cohort, BMPR2 mutation carriers have more severe PAH disease than noncarriers,
but this is only the case for females. Among carriers, patients with missense mutations that escape
nonsense-mediated decay have more severe disease than those with truncating mutations. These findings
suggest that treatment and prevention strategies directed specifically at BMPR2 pathway defects may need
to vary according to the type of mutation.
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Introduction
Pulmonary arterial hypertension (PAH) is a devastating
disease that affects people of all ages. The small pulmo-
nary arteries are primarily affected, resulting in progres-
sive pulmonary vascular remodeling that leads to
increased pulmonary vascular resistance and right heart
failure [1]. PAH may occur in a variety of clinical contexts,
including as a sporadic disease known as idiopathic PAH
(IPAH) and as a familial disease that typically occurs
among family members who share a common genetic pre-
disposition [2,3]. Germline mutations in the bone mor-
phogenetic protein receptor type 2 (BMPR2) gene, a
member of the transforming growth factor β superfamily,
are found in the majority of individuals (≥ 75%) with
PAH and a positive family history of the disease; in addi-
tion, BMPR2 mutations are found in 10-25% of cases of
sporadic PAH [4-7]. BMPR2-associated PAH is an auto-
somal dominant disease with reduced penetrance. There-
fore, the presence of a BMPR2 mutation in a patient with
PAH, regardless of family history, implies that the patient
has a heritable disease thus classified as heritable PAH
(HPAH).
IPAH and HPAH are histopathologically indistinguisha-
ble, and historically perceived to be clinically identical
[8]. Both display marked gender disparity, with ~2:1
female to male prevalence of each disease [9]. Despite
their similarities, recent studies have suggested that PAH
patients heterozygous for a BMPR2  mutation (carriers)
have more severe disease. There is growing data to support
this conclusion, as recent studies comparing HPAH
patients with a BMPR2 mutation to IPAH patients showed
that: (a) HPAH patients were less likely to respond to
acute vasodilator testing [10,11]; (b) HPAH patients pre-
sented at a younger age and with more severe hemody-
namic compromise at diagnosis [11,12]; (c) HPAH
patients had a shorter time to death or lung transplanta-
tion. [12]
Heterozygosity for a BMPR2 mutation is neither necessary
nor sufficient to cause HPAH. Disease severity among
affected carriers is not uniform, and reduced penetrance
(~20%) with variable age at both diagnosis and death sug-
gest the importance of modifiers of disease expression
[13]. Since different BMPR2 gene mutations have different
affects on BMPR2 protein production, they are likely to
cause differences in phenotype. For example, many
BMPR2  mutations are truncating or terminating muta-
tions that produce no functional protein product, due to
mRNA degradation via activation of the nonsense-medi-
ated decay (NMD) pathway [14]. NMD is a mechanism of
RNA surveillance used by the cell to destroy RNA tran-
scripts that would otherwise lead to the production of del-
eterious proteins. Thus, NMD may modify the phenotype
caused by a mutation (Figure 1; see also comprehensive
review by Neu-Yilik and Kulozik [14]). The expected result
of a mutation whose transcript is degraded by NMD is a
haploinsufficient (HI) effect due to insufficient protein
production, which may cause a less severe phenotype. The
vast majority, but not all, of truncating mutations activate
the NMD mechanism. On the other hand, a missense
mutation may result in a deleterious mutated protein
product that persists because it is not destroyed by NMD
[15,16].
While previous studies have demonstrated a difference in
severity between BMPR2 mutation carriers and noncarri-
ers, variations in severity according to BMPR2 mutation
have not been explored. Wide variation in the severity of
lung disease and survival is seen in other types of lung dis-
eases due to mutations in a single gene, such as cystic
fibrosis [17]. We hypothesized that the severity of HPAH
could vary according to the type of BMPR2 mutation. We
reasoned that carriers of a missense BMPR2 mutation that
escapes NMD would have more severe disease than those
who carry a truncating mutation. To test this hypothesis,
the Vanderbilt Pulmonary Hypertension Research Group
evaluated clinical data on all patients with PAH in whom
Model of the potential impact of Nonsense-Mediated Decay  (NMD) on protein expression Figure 1
Model of the potential impact of Nonsense-Mediated 
Decay (NMD) on protein expression. Activation of the 
NMD pathway results in the degradation of susceptible 
mutant transcripts, leaving only the remaining wild-type allele 
that produces normal BMPR2 protein. The individual may be 
susceptible to disease because protein amount is quantita-
tively but not qualitatively reduced, resulting in 'haploinsuffi-
ciency'. Mutant RNA transcripts that are resistant to NMD 
may result in a mutant protein with abnormal function, 
including the disruption of activity by normal BMPR2 protein 
produced by the normal allele. The potential deleterious 
effect of this qualitatively but not quantitatively altered pro-
tein can result in 'dominant negative' effects, and even 
greater susceptibility to disease.Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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genetic data were available. We found that for carriers of a
truncating BMPR2 mutation, disease severity was milder
and similar to that seen in noncarriers, while carriers of a
missense mutation had more severe disease.
Materials and methods
Study Population
The Vanderbilt Pulmonary Hypertension Research Cohort
contains clinical and biologic specimens collected over 25
years, including detailed family pedigree and medical his-
tories of patients with HPAH and IPAH. BMPR2 muta-
tions have been detected in a large proportion of subjects
tested to date. They consist of nonsense or terminating
mutations that are truncating, insertion-deletion muta-
tions that lead to splicing errors and frameshift mutations
(most of which are truncating), as well as missense muta-
tions.
One hundred and sixty-nine patients had genomic DNA
available (125 with a family history of PAH and 44 with
no family history) for complete BMPR2 mutation testing.
One-hundred and three of the 125 with a family history
were BMPR2 mutation carriers (82%), while 22 were non-
carriers (18%). Three of the 44 patients (7%) with no fam-
ily history and presumed IPAH were BMPR2  mutation
carriers who thus had heritable disease (HPAH). Consist-
ent with previous studies, patients from families with
multiple PAH patients with no evidence of a BMPR2
mutation were excluded from the analysis to decrease the
risk of misclassification in the BMPR2 noncarrier group.
Circulating lymphocytes were used to derive cell lines that
were used for puromycin-based NMD studies to deter-
mine the presence or absence of NMD from 96 of the 106
BMPR2 mutation carriers (Figure 2).
The majority of patients (55%) were not diagnosed and
treated at Vanderbilt University Medical Center (VUMC).
For those patients not diagnosed and treated at VUMC,
specialist physicians in their geographic regions identified
HPAH patients, and our investigators reviewed all medical
records for accuracy of diagnosis. We defined PAH diag-
nostically either by autopsy results showing plexogenic
pulmonary arteriopathy in the absence of alternative
causes such as congenital heart disease, or by clinical and
cardiac catheterization criteria. These criteria included a
mean pulmonary arterial pressure of more than 25 mm
Hg with a pulmonary capillary or left atrial pressure of less
than 15 mm Hg, and exclusion of other causes of pulmo-
nary hypertension in accordance with accepted interna-
tional standards of diagnostic criteria [3,18]. Clinical
information concerning survival in terms of death or lung
transplantation was up to date as of March 2009, the clos-
ing date for this study.
Vanderbilt Pulmonary Hypertension Research Cohort
study subjects were recruited via the Vanderbilt Pulmo-
nary Hypertension Center, the Pulmonary Hypertension
Association, and the NIH Clinical Trials website (http://
clinicaltrials.gov). The VUMC Institutional Review Board
approved all study protocols. All participants gave
informed written consent to participate in genetic and
clinical studies and underwent genetic counseling in
accordance with the guidelines of the American College of
Chest Physicians [19]. Samples were obtained at the time
of clinic visits or hospitalization or by mail via a kit for
collection of whole blood and DNA.
Genotyping and Genetic Analysis
Genomic DNA was isolated from whole blood using Pure-
gene® DNA Purification Kits (Gentra, Minneapolis, MN)
according to the manufacturer's protocol. We performed
BMPR2 gene mutation detection by sequencing exons and
exon intron boundaries of genomic DNA and reverse tran-
scriptase polymerase chain reaction (RT-PCR) analysis as
previously described. [20,21] All detected BMPR2 muta-
tions in this study have been previously reported, and are
included in a recent summary of detectable BMPR2 muta-
tions [22].
BMPR2  gene mutations were also assessed for NMD,
using protocols previously described. [16,23] Lym-
phocytes from each patient were incubated with and with-
out puromycin (250 μg/ml, Sigma-Aldrich, St. Louis,
MO), which inhibits NMD, for 16 hours before harvest-
ing. We classified mutant BMPR2  transcripts that were
degraded in the absence of puromycin as NMD active if
incubation with puromycin prevented this degradation.
NMD active BMPR2  mutations were demonstrated to
cause haploinsufficiency and classified as truncating.
Study subjects Figure 2
Study subjects. Samples from 169 consecutive subjects 
with PAH were tested for a BMPR2 mutation. Of these, 44 
were from patients who had no family history. The remaining 
125 were from patients who had a family history of PAH.Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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Mutations with transcripts not degraded in the absence or
presence of puromycin were demonstrated to be NMD
absent and these potentially dominant negative muta-
tions were classified as missense [15].
Statistical Analysis
Demographic and clinical features were compared
between  BMPR2  mutation carriers and noncarriers as
appropriate with the use of χ2 test or Fisher's exact test,
and student's t test or Mann-Whitney U test. The primary
study endpoint assessed was the continuous variable age
at diagnosis. Because PAH can present at any age, and is
characterized in some families by genetic anticipation,
individuals affected at an earlier age and those with a
shorter survival to death or lung transplantation may
express a more severe form of disease [12,24].
Kaplan-Meier survival curves were used to describe differ-
ences between groups in terms of age at diagnosis, as well
as survival from diagnosis to death or lung transplanta-
tion, with comparisons made using the log-rank test.
Ninety-five percent confidence intervals were reported, P
values less than 0.05 were considered statistically signifi-
cant, and all tests were two-tailed. Statistical analyses were
performed on a personal computer with the statistical
package SPSS for Windows (Version 16.0, SPSS, Chicago).
Of note, after careful analysis of the included subjects as
well as the pedigrees from each family included in the
study, it was concluded that the genetic relatedness of this
cohort was not sufficient or appropriate to justify the use
of family-based association tests that model genotypic
risks.
Results
Clinical Characteristics, BMPR2 Carriers versus 
Noncarriers
A BMPR2  mutation was identified in 3 of 44 subjects
(6.8%) with no family history, and 103 of 125 (82.4%) of
familial cases (Figure 2). After exclusion of the 22 subjects
with family history but no detectable BMPR2 mutation,
147 subjects were included in the analysis. This provided
comparison of the 41 BMPR2 mutation noncarriers to the
106 carriers, who have HPAH (Table 1).
The mean age at diagnosis was significantly younger in
BMPR2 mutation carriers (n = 106; 36.1 yrs, 95% C.I. 33.3
to 38.8) compared to noncarriers (n = 41; 42.0 yrs, 95%
C.I. 37.4 to 46.6) (P = 0.042; Table 1). Stratification by
gender revealed that these differences were only seen
among females (n = 103), in whom the mean age at diag-
nosis was significantly younger in the BMPR2 mutation
carriers (n = 72; 35.3 yrs, 95% CI 31.9 to 38.7), as com-
pared to noncarriers (n = 31; 43.7 yrs, 95% C.I. 38.5 to
48.9) (P = 0.015; Table 1). Of note, the proportion of
females with a pregnancy at the time of diagnosis or
within one year of diagnosis was not different between
groups (13.3% of noncarriers versus 16.7% of carriers, P =
0.77). While fewer males were available for analysis (n =
44), there was no difference in mean age at diagnosis
(37.5 versus 36.6 years) among males.
There were no significant differences between the two
groups in terms of hemodynamic characteristics at the
time of diagnosis, although differences in terms of
response to vasoreactivity testing were not evaluated
(Table 1). Survival data were available on 138 of 147
patients studied, with 11 subjects lost to follow up. Sev-
enty-three of the 138 patients died or underwent lung
transplantation (63 BMPR2 mutation carriers and 10 non-
carriers). Among those 73 patients, the 7 year difference in
mean age at death/lung transplantation was not signifi-
cantly different between carriers and noncarriers (36.6 yrs,
95% C.I. 32.9 to 40.3 versus 43.0 yrs, 95% C.I. 31.2 to
54.7; P = 0.389).
Location of the BMPR2 mutations
BMPR2 gene mutations among all carriers were detected
within the extracellular (n = 31), transmembrane (n = 11),
kinase (n = 40), and cytoplasmic (n = 15) functional
domains. One mutation was a large deletion across mul-
tiple domains, starting with the transmembrane domain.
The wide distribution of mutations by location in this rare
disease makes an investigation of phenotype according to
location an effort that would not be expected to yield
meaningful results, and a major reason that the use of
nonsense-mediated decay or other means to characterize
mutations phenotypically is appealing. Not surprisingly,
there was no difference in age at diagnosis or death
according to functional domain location of the BMPR2
mutations. In terms of their exonic locations, mutations
were located across the BMPR2 gene, from exon 1 to exon
Table 1: Clinical characteristics of patients at the time of 
diagnosis of PAH.
BMPR2 mutation Noncarriers
(n = 41)
Carriers
(n = 106)
P value*
Age at Diagnosis, yrs 42.0 (37.4-46.6) 36.1 (33.3-38.8) 0.04
Gender, female/male 3.1/1 2.2/1 0.43
RAP, mm Hg 12.4 (9.8-15.0) 11.1 (8.9-13.3) 0.29
Mean PAP, mm Hg 58.3 (55.0-61.5) 58.6 (55.3-61.8) 0.97
PCWP, mm Hg 10.1 (8.6-11.6) 10.6 (9.1-12.1) 0.77
CI, L/min/m2 1.8 (1.4-2.2) 1.9 (1.7-2.0) 0.92
PVR, mm Hg/L/min 14.0 (12.4-15.5) 18.1 (14.1-22.0) 0.08
SvO2, % 56.4 (52.6-60.3) 58.4 (54.5-62.3) 0.64
* All P values calculated using Mann-Whitney U test.
† 95% Confidence Interval values calculated using univariable ANOVA
Definition of abbreviations: CI = cardiac index; PAH = pulmonary 
arterial hypertension; PCWP = pulmonary capillary wedge pressure; 
PAP = pulmonary artery pressure; PVR = pulmonary vascular 
resistance; RAP = right atrial pressure; SvO2 = mixed venous oxygen 
saturation.Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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12, and no two families shared the same mutation. The
wide variation in location for the various mutations made
examining for phenotypic differences according to loca-
tion statistically unsound.
Clinical Characteristics, truncating versus missense 
BMPR2 mutations
Of the 96 BMPR2 mutations classified regarding NMD sta-
tus as truncating or missense, 55 (57.3%) had a truncating
mutation and 41 (42.7%) had a missense mutation
(Table 2; Figure 2). There was no difference according to
gender, with truncating mutations found in 60% of males
and 50% of females (P = 0.38). However, there was a sig-
nificant difference in mean age at diagnosis for these sub-
jects, with PAH diagnosed in patients with truncating
mutations 10 years later than in missense mutations
(truncating mutations 39.9 years (95% C.I. 36.3 to 43.5)
versus missense mutations 30.6 years (95% C.I. 25.9 to
35.3); P = 0.004). These findings also suggested that the
difference in age at diagnosis between BMPR2 carriers and
noncarriers noted in this study and by previous studies
was not equal for truncating and missense mutations. In
fact, while there was a substantial difference between car-
riers with a missense mutation and noncarriers (P  =
0.002), there was no difference between patients with a
truncating mutation and noncarriers (Figure 3). Due to
limitations of sample size, comparisons between those
with missense and truncating mutations were not made
according to gender.
Hemodynamic parameters were not significantly different
between patients with missense compared to those with
truncating mutations, although differences in terms of
response to vasoreactivity testing were not evaluated.
Survival, truncating versus missense BMPR2 mutations
Survival data were available on 91 of the 96 patient sam-
ples analyzed for NMD pathway activation for mutation
classification. Sixty-one of the 91 patients died (31 with
truncating mutations and 30 with missense mutations).
The use of a systemic prostanoid medication, such as epo-
prostenol, was not different between groups, with this
class of medication used by 68.0% of patients with a trun-
cating mutation and 82.1% of patients with a missense
mutation (P = 0.151). Survival was different between the
two groups, with a significantly shorter time to death or
lung transplantation for patients with a missense muta-
tion compared to those with a truncating mutation (1832
days, 95% CI 1272 to 2394 versus 3648 days, 95% CI
2304 to 4991; log rank test, P = 0.044) (Figure 4). In addi-
tion, the mean age at death/transplantation was signifi-
cantly younger in the missense mutation group compared
to the truncating mutation group (32.4 yrs, 95% CI 26.9
to 38.0 versus 42.0 yrs, 95% CI 37.4 to 46.6; P = 0.014).
Penetrance, according to mutation type and age
An exact evaluation of penetrance among BMPR2 muta-
tion carriers is currently not possible due to the inherent
ascertainment bias associated with the collection of sub-
ject specimens; our cohort is enriched for patients with a
BMPR2 mutation compared to unaffected mutation carri-
ers. However, due to the differences in age at diagnosis
and death among patients with missense and truncating
mutations, we examined disease penetrance as a function
of age. Due to the differences in age at diagnosis and death
among patients with missense and truncating mutations,
we examined disease penetrance as a function of age. The
mean age at diagnosis for the entire cohort (36 years) was
chosen a priori as a dividing point for this evaluation. We
found a statistically significant difference in penetrance in
the comparison of the missense mutation group versus
the truncating mutation group (P = 0.01), with 68.3% of
carriers of a missense mutation diagnosed prior to age 36
years, versus 41.3% of carriers of a truncating mutation
(Figure 5). Of the 65 females within this analysis, 33 were
diagnosed prior to age 36 years (18 within the missense
versus 15 within the truncating mutation groups); 5 of the
missense (27.8%) versus 4 of the truncating (26.7%)
Table 2: Clinical characteristics of patients at the time of diagnosis of PAH, according to NMD pathway status of the BMPR2 mutation.
NMD status of BMPR2 mutation 'NMD active' (Truncating)
(n = 55)
'NMD absent' (Missense)
(n = 41)
P value*
Age at Diagnosis, yrs 39.9 (36.3-43.5) 30.6 (25.9-35.3) 0.004
Gender, female/male 2.6/1 1.7/1 0.82
RAP, mm Hg 11.4 (7.4-15.3) 10.5 (8.1-13.0) 0.74
Mean PAP, mm Hg 56.5 (51.6-61.5) 60.0 (54.9-65.2) 0.42
PCWP, mm Hg 11.1 (8.5-13.6) 10.3 (8.4-12.2) 0.74
CI, L/min/m2 1.8 (1.5-2.1) 1.9 (1.8-2.1) 0.16
PVR, mm Hg/L/min 18.4 (11.4-25.3) 17.9 (12.7-23.1) 0.78
SvO2, % 58.6 (51.2-65.3) 57.3 (52.8-61.7) 0.19
* All P values calculated using Mann-Whitney U test.
† 95% Confidence Interval values calculated using univariable ANOVA
Definition of abbreviations: CI = cardiac index; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; PAP = 
pulmonary artery pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; SvO2 = mixed venous oxygen saturation.Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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mutation groups were females diagnosed during or within
one year of pregnancy.
Discussion
We studied 169 patients with HPAH and IPAH with and
without germline BMPR2 mutations, all treated at centers
in the United States according to the best standard of care
available. Our results support the concept that patients
who are carriers of a BMPR2 mutation have more severe
disease than noncarriers. Specifically, our results support
the findings of other investigative groups that patients
with a BMPR2 mutation presented at a younger age and
had a shorter time to death or lung transplantation, while
not supporting the conclusion that carriers have worse
hemodynamics at the time of diagnosis [11,12]. However,
we found that this is only true among females and that
patients with missense mutations have more severe dis-
ease than patients with truncating mutations (Figures 1, 3,
4, 5). Significant differences in severity among those with
a missense mutation are characterized by a younger age at
diagnosis, younger age at death, and a shorter survival
from diagnosis to death or transplant. Because these are
well described indicators of disease severity, our findings
suggest that in HPAH whether or not a BMPR2 mutation
results in a stable (missense mutation) or unstable (trun-
cating mutation) mRNA transcript is a critical modifying
variable of severity [12,25,26]. As a result, therapies for
treatment and prevention directed specifically at BMPR2
pathway defects may need to vary according to the type of
mutation. For example, efforts are underway to identify
drugs that would increase BMPR2 gene expression as a
method of treatment and perhaps disease prevention. For
carriers of an unstable mRNA transcript due to a truncat-
Age at diagnosis of PAH: comparison of noncarriers, patients  carrying a truncating BMPR2 mutation, and patients carrying a  missense BMPR2 mutation Figure 3
Age at diagnosis of PAH: comparison of noncarriers, 
patients carrying a truncating BMPR2 mutation, and 
patients carrying a missense BMPR2 mutation. Age at 
diagnosis is no different between noncarriers and patients 
carrying a truncating BMPR2 mutation. There is a significant 
difference in age at diagnosis between noncarriers and 
patients carrying a missense BMPR2 mutation (*, P = 0.002). 
Values represent mean age at diagnosis; error bars represent 
95% confidence intervals.
Outcome of BMPR2 mutation carriers with HPAH: truncating  versus missense mutation carriers Figure 4
Outcome of BMPR2 mutation carriers with HPAH: 
truncating versus missense mutation carriers. Survival 
measured as time to death or lung transplantation, compared 
between the two groups. Survival is shorter among carriers 
with a missense mutation (log rank test, P = 0.044).
Penetrance of PAH as a function of age Figure 5
Penetrance of PAH as a function of age. Statistically sig-
nificant difference in penetrance according to genotype and 
age in the comparison of the missense mutation group versus 
the truncating mutation group (P = 0.01).Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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ing mutation, such therapies that directly increase BMPR2
expression might safely and effectively prevent or treat dis-
ease by increasing expression by the normal allele without
changing the mutated allele's product (because it is inher-
ently unstable). However, such a strategy could be detri-
mental in carriers of a mutation that produces a stable
mRNA transcript associated with more severe disease,
since increasing BMPR2 expression could increase both
normal allele and mutant allele expression. The effort to
tailor therapies to the type of gene mutation is consistent
with efforts currently being pursued in the study of other
genetic diseases, such as cystic fibrosis [27].
The functional impact of specific BMPR2 mutations has
been incompletely investigated to date, with variable con-
sequences for signaling activity reported [28,29]. Nor-
mally, BMPs regulate growth, differentiation, and
apoptosis via an intracellular signaling cascade mediated
via cytoplasmic signaling proteins known as Smads, as
well as via Smad-independent pathways. The Smad family
of proteins are responsible for transforming growth factor
β receptor signaling to regulate gene expression [30].
There is a delicate balance of Smad signaling among the
transforming growth factor β receptors, and disruption of
this balance may promote a milieu amenable to the devel-
opment of pulmonary vascular disease among susceptible
subjects [7]. This study supports previous suggestions that
truncating and missense BMPR2 mutations may differen-
tially impact BMP pathway signaling, and further suggests
that they do so via their differential activation of NMD
[31]. NMD is a mechanism by which mRNA molecules
produced by truncating mutations are detected and elim-
inated by the cell, resulting in no functional protein from
the mutated allele. This produces a haploinsufficient
effect, which magnifies the importance of the wild-type
allele in protein production. Consistent with this, we
recently found that the level of expression of wild-type
BMPR2 allele is a critical factor in the pathogenesis of
HPAH caused by truncating mutations [32]. In contrast,
missense mutations resistant to NMD destruction may
produce a mutant protein product with deleterious effects
that impair or completely block the activity of the remain-
ing normal allele. This may create a 'dominant negative
effect', which affects the phenotype more severely
(Figure 1) [16,22].
The comparison of a truncating versus missense mutation
may be particularly important for BMP pathway signaling,
which is dependent upon appropriate heterodimerization
of BMPR2 with type 1 BMP receptors to activate the sign-
aling cascade. Correct signaling requires the proper stoi-
chiometric balance between receptors [33]. While this
balance is likely perturbed by most types of BMPR2 muta-
tions, it can be exaggerated by missense mutations, which
cause dysfunctional heterodimers that exert dominant
negative effects on BMP signaling [34]. Thus, as reported
in other genetic diseases, the activation or inactivation of
the NMD pathway may profoundly affect the variability of
disease phenotypes in HPAH, and our findings support
this concept [16,35]. From a therapeutic perspective,
manipulation of the NMD surveillance pathway specific
to a particular BMPR2  mutation might promote a less
severe phenotype by changing a dominant negative effect
to haploinsufficiency [36].
This study demonstrates how different variations within
the same gene may influence disease, although several
areas of potential criticism exist. First, because the inci-
dence of HPAH is very low (~1 case per 1 million adults)
and this study requires the creation of cell lines from each
patient, like other studies of rare diseases the overall
number of patients enrolled is relatively small and the col-
lection of a replicate cohort will take many years [37].
Such an endeavor will require a multicenter collaborative
effort, and the design and implementation of that investi-
gation in an independent study population is currently
underway. Second, it is possible that the 22 patients with
familial PAH excluded from analysis because they did not
carry a detectable BMPR2 mutation do carry mutations in
unexplored parts of the BMPR2 gene (or that they have
inappropriately been categorized as having a familial dis-
ease but are in fact patients with IPAH). However, our use
of genomic DNA and transcript sequencing and MLPA
analysis provided the most comprehensive screen for
BMPR2 mutations described to date [20]. Third, because
not every truncating genetic mutation predicted to acti-
vate the NMD pathway based upon the genotype truly
activates NMD (rarely, some do not), cell line testing is
required for confirmation as performed in this study. For
this reason, subjects were divided for analysis according to
the results of cell line testing for NMD pathway activity,
not according to predicted activity (in fact, 7 of 96 subjects
with cell lines tested for NMD had mutations predicted to
result in activation of the NMD pathway that upon testing
were not 'NMD active'). Regardless, the key issue is
whether or not the mutation is capable of activating the
NMD pathway or not, and the vast majority of truncating
mutations do activate this pathway. Finally, the absence
of significant differences in cardiovascular parameters at
diagnosis in this study suggests that additional factors par-
ticipate in the generation of phenotype, especially high-
lighting the importance of right heart adaptation to
pulmonary vascular disease and the relatively small
degree to which we currently understand this process at
the cellular, molecular and clinical levels [38]. Efforts are
underway to determine whether the response to acute
vasodilator testing at the time of diagnosis is different
between patients with truncating and missense muta-
tions, as response data may predict survival. [39]Respiratory Research 2009, 10:87 http://respiratory-research.com/content/10/1/87
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In conclusion, this study supports previous studies show-
ing increased severity among patients with a BMPR2
mutation compared to those who are noncarriers, but
interestingly this is only true for females and for carriers of
a certain type of mutation. When we classify mutations
according to if they activate (truncating mutations) or
escape (missense mutations) NMD destruction of their
mutant transcript we see a significant difference in severity
between these groups. This supports the concept that mis-
sense mutations that escape NMD result in stable tran-
scripts that may produce proteins that are qualitatively
different. Their resultant dominant negative effects on
BMP signaling make missense mutations more detrimen-
tal than truncating mutations, which cause haploinsuffi-
ciency. The haploinsufficient effects of truncating
mutations occur because the total BMPR2 protein levels
are quantitatively reduced to the level of expression of the
single wild-type allele. These findings emphasize the need
to further explore the manner in which different sub-
classes of BMPR2 mutations influence phenotype in PAH,
as well as the potential role of the wild-type allele.
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